DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Estimate your regain trajectory and see what GLP‑1s actually achieve after surgery — with an honest account of how strong that evidence is, which is less strong than most sites imply. Or use a GLP‑1 as a bridge to (or an alternative to) surgery.
What GLP-1s actually achieve after bariatric surgery
The best available evidence is a 2025 systematic review pooling eight retrospective studies of 964 post-surgical patients: average total weight loss of about 13.6% on tirzepatide and 11.0% on semaglutide. Note the word retrospective — there is no completed randomized trial in this population, so these figures likely flatter the drugs a little (the people who seek out and stay on treatment are not the same as those who do not). A dedicated randomized trial, BARI-STEP, is still running.
If another site quotes you a precise post-bariatric number from SURMOUNT-4 or STEP 10, it is wrong: SURMOUNT-4 was a treatment-withdrawal trial and STEP 10 enrolled people with prediabetes. Neither study included a single bariatric-surgery patient.
One practical upside: insurance approval is usually easier with a documented surgical history, since most plans treat inadequate response to surgery as a clear medical-necessity criterion.
Your bariatric history
Based on long-term bariatric outcome data (STAMPEDE, Swedish Obese Subjects) for sleeve gastrectomy (vsg). Asymptotic curve — most regain happens years 1-3, plateauing toward year 5.
Most common bariatric procedure. Regain rates higher than RYGB at 5+ years — about 30% of patients regain >10% of total weight lost.
GLP-1s for post-bariatric regain are supported by retrospective data only — a 2025 review of eight studies (n=964) found about 13.6% total weight loss on tirzepatide and 11.0% on semaglutide, with no completed randomized trial yet. Insurance approval is typically easier with a documented bariatric history.
~13.6% total weight loss in the 2025 pooled post-bariatric review (retrospective) — the larger of the two effects. The review did not break results out by surgery type, so do not expect a sleeve-specific figure.
~11.0% total weight loss in the 2025 pooled post-bariatric review (retrospective). The review did not break results out by surgery type, so do not expect a sleeve-specific figure.
Orforglipron — an oral small-molecule GLP-1. Useful if a VSG patient has gastric outlet issues making weekly injections challenging.
Coordinate with your bariatric team. They have your full history (anatomy, nutrient status, prior weight trajectory) — GLP-1 dosing for post-bariatric patients differs from general obesity protocols.
Surgical alterations to the GI tract eventually adapt. Stretching of the stomach pouch, hormonal counter-regulation, and behavioral patterns return. About 30% of sleeve patients and 20% of bypass patients regain >10% of total weight lost within 5 years.
It works, but the evidence is weaker than for people who never had surgery — and you should know that before you decide. A 2025 systematic review pooled eight retrospective studies covering 964 post-surgical patients: average total weight loss was about 13.6% on tirzepatide and about 11.0% on semaglutide. Every one of those studies was retrospective. There is no completed randomized controlled trial of a GLP-1 for post-bariatric weight regain — a dedicated trial (BARI-STEP) is still running. Retrospective data can overstate a drug's effect, because the patients who seek out and stay on treatment differ from those who do not. Treat these numbers as a reasonable expectation, not a guarantee. Be sceptical of any site quoting you a precise post-bariatric figure from SURMOUNT-4 or STEP 10: neither trial enrolled bariatric-surgery patients at all.
Most clinicians wait at least 1 year post-op to evaluate natural weight trajectory. Earlier initiation can mask surgical effects and complicate nutrient absorption assessment. After year 1, start when weight regain >5-10% of nadir is documented.
Yes, as bridge therapy. Many bariatric programs require 5-10% pre-op weight loss; GLP-1s help achieve this. Most surgeons require 1-2 week pre-op discontinuation due to anesthesia aspiration risk from delayed gastric emptying.
Increasingly common. Patients achieving 15-20% weight loss on Zepbound or Wegovy often defer or cancel surgery plans. Discuss with both an obesity medicine specialist and a bariatric surgeon — they can help evaluate whether surgery still offers benefit for your specific case.
Regain trajectories are drawn from long-term bariatric outcome data (STAMPEDE and the Swedish Obese Subjects cohort); the GLP-1 figures come from the 2025 systematic review of eight retrospective post-bariatric studies (n=964). Deliberately absent: SURMOUNT-4 and STEP 10, which are frequently miscited on this topic but enrolled no bariatric patients. Your actual trajectory varies by adherence, baseline metabolism, and surgical anatomy. Always coordinate with your bariatric team.
Pre-bariatric considerations →·Zepbound review·Our methodology